Diarylpyridine anti-viral compounds
Disclosed herein are compounds and related compositions for the treatment of viral infection, including RNA viral infection, and compounds that can modulate the RIG-I pathway in vertebrate cells, including compounds that can activate the RIG-I pathway.
1. A pharmaceutical composition comprising an immune-modulating compound having a structure
wherein:
R 1 is CF 3 , NO 2 , C(═O)OR 6 , or C(═O)NR 6 R 7 ,
R 2 is H, lower alkyl, Br, Cl, or F,
R 4 is CN,
R 5 is H or lower alkyl,
R 6 and R 7 are each independently H or lower alkyl; and
n=1, 2, 3, 4, or 5.
2. A pharmaceutical composition comprising a pharmaceutically acceptable salt, tautomer, isomer and/or prodrug of the immune-modulating compound of claim 1 .
3. A pharmaceutical composition of claim 1 wherein the immune-modulating compound has a structure
4. A pharmaceutical composition of claim 1 , wherein the immune-modulating compound has a structure
5. A pharmaceutical composition of claim 1 , wherein the immune-modulating compound has a structure
6. A pharmaceutical composition of claim 1 wherein R 1 is CF 3 , NO 2 , C(═O)OH, or C(═O)NH 2 , R 2 is H, CH 3 , Br, or F, and R 5 is H.
7. A pharmaceutical composition of claim 1 wherein R 1 is OCH 3 , R 2 is Br, or F, and R 5 is H.
8. A pharmaceutical composition comprising an immune-modulating compound having a structure
wherein:
R 1 is selected from H, lower alkyl, OCH 3 , CF 3 , OH, NO 2 , Br, Cl, F, C(═O)R 6 , or C(═O)NR 6 R 7 ,
R 2 is selected from Br, F, or Cl,
R 4 is CN,
R 5 is H or lower alkyl,
R 6 and R 7 are each independently selected from H or lower alkyl; and
n=1, 2, 3, 4, or 5.
9. A pharmaceutical composition of claim 1 , wherein the immune-modulating compound has a structure
10. A pharmaceutical composition of claim 8 , wherein the immune-modulating compound has a structure
11. A method of treating a viral infection in a vertebrate comprising administering to the vertebrate a pharmaceutical composition of claim 1 , wherein the viral infection is caused by a virus from one or more of the following families: Flaviviridae, or Orthomyxoviridae.
12. A method of claim 11 wherein the viral infection is influenza virus, Hepatitis C virus, or West Nile virus.
13. A method of claim 11 wherein said method comprises vaccinating a vertebrate by additionally administering a vaccine against influenza virus, Hepatitis C virus, or West Nile virus.
14. A method of claim 11 wherein the immune-modulating compound has a structure selected from the group consisting of
15. A method of treating a viral infection in a vertebrate comprising administering to the vertebrate an immune-modulating compound pharmaceutical composition of claim 7 wherein the viral infection is caused by a virus from one or more of the following families: Flaviviridae or Orthomyxoviridae.